Publicaciones en colaboración con investigadores/as de Hospital Universitario Puerta del Mar (22)

2022

  1. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response

    World Journal of Hepatology, Vol. 14, Núm. 1, pp. 62-79

2021

  1. Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 9, pp. 1863-1871

  2. Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs

    Scientific Reports, Vol. 11, Núm. 1

2014

  1. Protocolo diagnóstico diferencial del paciente con fiebre aguda sin focalidad infecciosa

    Medicine (Spain), Vol. 11, Núm. 50, pp. 2973-2976

  2. Protocolo diagnóstico diferencial del paciente con fiebre y manifestaciones clínicas hemorrágicas

    Medicine (Spain), Vol. 11, Núm. 50, pp. 2987-2990

  3. Protocolo diagnóstico y tratamiento empírico del paciente con infección por el VIH con sintomatología respiratoria

    Medicine (Spain), Vol. 11, Núm. 49, pp. 2928-2932

  4. Tratamiento de la infección por el VIH

    Medicine (Spain), Vol. 11, Núm. 49, pp. 2912-2919

2011

  1. Bacterial translocation in HIV-infected patients with HCV cirrhosis: Implication in hemodynamic alterations and mortality

    Journal of Acquired Immune Deficiency Syndromes, Vol. 56, Núm. 5, pp. 420-427

2008

  1. Role of pegylated interferon-α-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients

    Clinical Pharmacology and Therapeutics, Vol. 84, Núm. 5, pp. 573-580

2007

  1. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: A prospective multicentre study

    Antiviral Therapy, Vol. 12, Núm. 6, pp. 899-907

  2. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 12, Núm. 8, pp. 1225-1235

  3. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients

    Antiviral Therapy, Vol. 12, Núm. 4, pp. 523-529

  4. What length of follow-up in patients with HIV and hepatitis C virus coinfection is necessary to consider the level of transaminases to be "persistently normal"? [1]

    Clinical Infectious Diseases

2006

  1. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C

    Antiviral Therapy, Vol. 11, Núm. 7, pp. 839-846

  2. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 58, Núm. 1, pp. 140-146

  3. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

    Gut, Vol. 55, Núm. 3, pp. 409-414

  4. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease

    AIDS, Vol. 20, Núm. 1, pp. 49-57

  5. T cell receptor excision circles (TRECs), CD4+, CD8+ and their CD45RO+ and CD45RA+ subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: Analysis in a population on effective antiretroviral therapy

    Clinical and Experimental Immunology, Vol. 146, Núm. 2, pp. 270-277

2004

  1. Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study

    Clinical Infectious Diseases, Vol. 38, Núm. 1, pp. 128-133

  2. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: Differences between pegylated and standard interferon

    Clinical Microbiology and Infection, Vol. 10, Núm. 12, pp. 1067-1074